Staphylococcal toxic shock syndrome: Mechanisms and management

Current Infectious Disease Reports

Volumn 12, Issue 5, 2010, Pages 392-400

  Silversides, Jonathan A ^a   Lappin, Emma ^b   Ferguson, Andrew J ^c  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

Clindamycin; Cytokine; Daptomycin; Early goal directed therapy; Gram positive; Immunoglobulin; Immunomodulation; Infection; Interleukin 10; Linezolid; Methicillin resistant Staphylococcus aureus (MRSA); Nuclear factor B; Pathogen associated molecular patterns (PAMP); Polymorphism; Septic shock; Staphylococcus aureus; Superantigen; Systemic inflammatory response syndrome; T cell receptor; Tigecycline; Toll like receptor; Toxic shock syndrome; Toxic shock syndrome toxin 1; Tumor necrosis factor

Indexed keywords

CLARITHROMYCIN; CLINDAMYCIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOBUTAMINE; DOPAMINE; DROTRECOGIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LINEZOLID; NAFCILLIN; NORADRENALIN; OXYGEN; RIFAMPICIN; STAPHYLOCOCCUS ENTEROTOXIN; SUPERANTIGEN; TEICOPLANIN; TIGECYCLINE; TOLL LIKE RECEPTOR 2; TOXIC SHOCK SYNDROME TOXIN 1; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENDOTRACHEAL INTUBATION; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; HUMAN; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; REVIEW; RISK FACTOR; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; TOXIC SHOCK SYNDROME; UNSPECIFIED SIDE EFFECT;

EID: 77956266093     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0119-y     Document Type: Review

References (50)

1. J Todd M Fishaut F Kapral, et al. 1978 Toxic-shock syndrome associated with phage-group-1 staphylococci Lancet 2 1116 1118 10.1016/S0140-6736(78)92274- 2 1:STN:280:DyaE1M%2FntFOhsw%3D%3D 82681
2. RA Hajjeh A Reingold A Weil, et al. 1999 Toxic shock syndrome in the United States: surveillance update, 1979-1996 Emerg Infect Dis 5 807 810 10.3201/eid0506.990611 1:STN:280:DC%2BD3c%2FntVCgtQ%3D%3D 10603216
3. Centers for Disease Control and Prevention (CDC) 2010 Notifiable diseases and mortality tables MMWR 59 398 411
4. PM Schlievert TJ Tripp ML Peterson 2004 Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St Paul, Minnesota, during the 2000-2003 surveillance period J Clin Microbiol 42 2875 2876 10.1128/JCM.42.6.2875-2876. 2004 15184497
5. HFL Wertheim DC Melles MC Vos, et al. 2005 The role of nasal carriage in Staphylococcus aureus infections Lancet Infect Dis 5 751 762 10.1016/S1473-3099(05)70295-4 16310147
6. ME Guinan BB Dan RJ Guidotti, et al. 1982 Vaginal colonization with Staphylococcus aureus in healthy women Ann Intern Med 96 944 947 1:STN:280:DyaL383ivFWhsg%3D%3D 7046548
7. S Schlebusch JM Schooneveldt F Huygens, et al. 2009 Prevalence of Staphylococcus aureus strains in an Australian cohort, 1989-2003: evidence for the low prevalence of the toxic shock toxin and Panton-Valentine leukocidin genes Eur J Clin Microbiol Infect Dis 28 1183 1189 10.1007/s10096-009-0761-1 1:STN:280:DC%2BD1MnmtVOmuw%3D%3D 19466470
8. J Parsonnet MA Hansmann ML Delaney, et al. 2005 Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women J Clin Microbiol 43 4628 4634 10.1128/JCM.43.9.4628-4634.2005 1:CAS:528:DC%2BD2MXhtVOrtLnO 16145118
9. G Durand M Bes H Meugnier, et al. 2006 Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France J Clin Microbiol 44 847 853 10.1128/JCM.44.3.847-853.2006 1:CAS:528:DC%2BD28XjsVyltbg%3D 16517865
10. J Parsonnet RV Goering MA Hansmann, et al. 2008 Prevalence of toxic shock syndrome toxin 1 (TSST-1)-producing strains of Staphylococcus aureus and antibody to TSST-1 among healthy Japanese women J Clin Microbiol 46 2731 2738 10.1128/JCM.00228-08 18550735
11. RR Souza LR Coelho AMN Botelho, et al. 2009 Biofilm formation and prevalence of lukF-pv, seb, sec and tst genes among hospital- and community-acquired isolates of some international methicillin-resistant Staphylococcus aureus lineages Clin Microbiol Infect 15 203 207 10.1111/j.1469-0691.2008.02118.x 1:CAS:528:DC%2BD1MXkslGqtbw%3D 19191789
12. B Limbago GE Fosheim V Schoonover, et al. 2009 Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis J Clin Microbiol 47 1344 1351 10.1128/JCM.02264-08 19321725
13. D Hu K Omoe F Inoue, et al. 2008 Comparative prevalence of superantigenic toxin genes in meticillin-resistant and methicillin susceptible Staphylococcus aureus isolates J Med Microbiol 57 1106 1112 10.1099/jmm.0.2008/002790-0 18719180
14. JD Fraser T Proft 2008 The bacterial superantigen and superantigen-like proteins Immunol Rev 225 226 243 10.1111/j.1600-065X.2008.00681.x 1:CAS:528:DC%2BD1cXht1CmtbnP 18837785 A thorough and useful overview of the current knowledge of superantigen structure, activity, and the pathophysiology of superantigen-mediated disease
15. J White A Herman AM Pullen, et al. 1989 The V-beta specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice Cell 56 27 35 10.1016/0092-8674(89)90980-X 1:CAS:528: DyaL1MXptlWkug%3D%3D 2521300
16. M Llewelyn J Cohen 2002 Superantigens: microbial agents that corrupt immunity Lancet Infect Dis 2 156 162 10.1016/S1473-3099(02)00222-0 1:CAS:528:DC%2BD38XisVWntbo%3D 11944185
17. D Thomas O Dauwalder V Brun, et al. 2009 Staphylococcus aureus superantigens elicit redundant and extensive human Vβ patterns Infect Immun 77 2043 2050 10.1128/IAI.01388-08 1:CAS:528:DC%2BD1MXlsFSkuro%3D 19255190 This study goes into considerable depth to elucidate specific superantigen Vβ signatures, although the authors found significant variation and overlap in Vβ T-cell responses to staphylococcal superantigens
18. JK McCormick JM Yarwood PM Schlievert 2001 Toxic shock syndrome and bacterial superantigens: an update Annu Rev Microbiol 55 77 104 10.1146/annurev.micro.55.1.77 1:CAS:528:DC%2BD3MXnslKjt74%3D 11544350
19. L Faulkner A Cooper C Fantino, et al. 2005 The mechanism of superantigen mediated toxic shock: not a simple Th1 cytokine storm J Immunol 175 6870 6877 1:CAS:528:DC%2BD2MXhtF2ju7jN 16272345
20. NS Trede E Castigli RS Geha, et al. 1993 Microbial superantigens induce NF-kappa B in the human monocytic cell line THP-1 J Immunol 150 5604 5613 1:CAS:528:DyaK3sXlsFehtL4%3D 8515079
21. P Hopkins AC Pridmore S Ellmerich, et al. 2008 Increased surface toll-like receptor 2 expression in superantigen shock Crit Care Medicine 36 1267 1276 10.1097/CCM.0b013e31816a0a78 1:CAS:528:DC%2BD1cXktVCntLg%3D
22. A Iwasaki R Medzhitov 2010 Regulation of adaptive immunity by the innate immune system Science 327 291 295 10.1126/science.1183021 1:CAS:528: DC%2BC3cXktlWkuw%3D%3D 20075244 This article provides a very good review of the process of pathogen recognition by the host, including secreted, transmembrane, and cytosolic receptors for pathogen-associated molecular patterns
23. TA Chau ML McCully W Brintnell, et al. 2009 Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome Nat Med 15 641 649 10.1038/nm.1965 1:CAS:528:DC%2BD1MXmtlakurc%3D 19465927 This study offers a potential explanation for the low frequency of toxic shock syndrome despite widespread colonization and infection, based on the ability of TLR2 activation to modulate inflammation
24. •• Mele T, Madrenas J: TLR2 signalling: at the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus. Int J Biochem Cell Biol 2010 (Epub ahead of print). An excellent review highlighting the potential for TLR2-mediated immunomodulation and the impact of a dual pro- and anti-inflammatory outcome from staphylococcal exposure on our approach to TSS.
25. A Brosnahan MJ Mantz CA Squier, et al. 2009 Cytolysins augment the superantigen penetration of stratified mucosa J Immunol 182 2364 2373 10.4049/jimmunol.0803283 1:CAS:528:DC%2BD1MXhsFKrsL8%3D 19201891
26. SJ Stolz JP Davis JM Vergeront, et al. 1985 Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin J Infect Dis 151 883 889 1:STN:280:DyaL2M7osVSquw%3D%3D 3989322
27. M Llewelyn S Sriskandan M Peakman, et al. 2004 HLA class II polymorphisms determine responses to bacterial superantigens J Immunol 172 1719 1726 1:CAS:528:DC%2BD2cXptl2isQ%3D%3D 14734754
28. LJ Strausburgh 1993 Toxic shock syndrome: are you recognizing its changing presentations? Postgrad Med 94 107 108
29. LM El-Fiky N Khamis D Mostafa Bel AM Adly 2009 Staphylococcal infection and toxin production in chronic rhinosinusitis Am J Rhinol Allergy 23 264 267 10.2500/ajra.2009.23.3313 19490799
30. KH Chan TL Kraai GT Richter, et al. 2009 Toxic shock syndrome and rhinosinusitis in children Arch Otolaryngol Head Neck Surg 135 538 542 10.1001/archoto.2009.55 19528399
31. M Wharton Tl Chorb RL Vogt, et al. 1990 Case definitions for public health surveillance MMWR Recomm Rep 39 1 43 1:STN:280:DyaK3M%2Fkt1ejug%3D%3D 2122225
32. M Waclavicek N Stich I Rappan, et al. 2009 Analysis of the early response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to TSST-1 J Leukoc Biol 85 44 54 10.1189/jlb.0108074 1:CAS:528:DC%2BD1MXjt12jsg%3D%3D 18923105
33. K Granger MS Rundell MR Pingle, et al. 2010 Multiplex PCR-ligation detection reaction assay for simultaneous detection of drug resistance and toxin genes from Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium J Clin Microbiol 48 277 280 10.1128/JCM.01411-09 1:CAS:528: DC%2BC3cXhvFKqu7g%3D 19864481
34. V Javid Khojasteh MT Rogan V Edwards-Jones, et al. 2003 Detection of antibodies to Staphylococcus aureus toxic shock syndrome toxin-1 using a competitive agglutination inhibition assay Lett Appl Microbiol 36 372 376 10.1046/j.1472-765X.2003.01330.x 1:STN:280:DC%2BD3s3jtFKkug%3D%3D 12753244
35. T Ferry D Thomas T Perpoint, et al. 2008 Analysis of superantigenic toxin Vb T-cell signatures produced during cases of staphylococcal toxic shock syndrome and septic shock Clin Microbiol Infect 14 546 554 10.1111/j.1469-0691. 2008.01975.x 1:STN:280:DC%2BD1c3pvF2msQ%3D%3D 18373692
36. T Ferry D Thomas J Bouchut, et al. 2008 Early diagnosis of staphylococcal toxic shock syndrome by detection of the tsst-1 v beta signature in peripheral blood of a 12-year-old boy Ped Infect Dis J 27 274 277 10.1097/INF. 0b013e31815c93a3
37. H Gbaguidi-Haore M Thouverez G Couetdic, et al. 2009 Usefulness of antimicrobial resistance pattern for detecting PVL- or TSST-1-producing methicillin resistant Staphylococcus aureus in a French university hospital J Med Microbiol 58 1337 1342 10.1099/jmm.0.010116-0 19556369 This useful paper demonstrates the potential to determine the likelihood of toxin production by MRSA based on local antimicrobial resistance pattern, once a reference study on toxin production by local isolates has been done
38. RP Dellinger MM Levy JM Carlet, et al. 2008 Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Int Care Med 34 17 60 10.1007/s00134-007-0934-2 This article provides an evidence-based, worldwide, consensus statement on current therapy for sepsis and septic shock, emphasizing the importance of early intervention and attention to detail
39. E Rivers B Nguyen S Havstad, et al. 2001 Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 345 1368 1377 10.1056/NEJMoa010307 1:STN:280:DC%2BD38%2FmsFGjtA%3D%3D 11794169
40. AE Jones NI Shapiro S Trzeciak, et al. 2010 Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial JAMA 303 739 746 10.1001/jama.2010.158 1:CAS:528:DC%2BC3cXisFGntLk%3D 20179283 This article describes a randomized controlled trial of two resuscitation endpoints, demonstrating noninferiority of the more readily measured lactate clearance as compared to central venous oxygen saturation
41. D DeBacker P Biston J Devriendt, et al. 2010 Comparison of dopamine and norepinephrine in the treatment of shock N Engl J Med 362 779 789 10.1056/NEJMoa0907118 1:CAS:528:DC%2BC3cXivV2hu7k%3D
42. V Gupta P Datta H Rani J Chander 2009 Inducible clindamycin resistance in Staphylococcus aureus: a study from North India J Postgrad Med 55 176 179 10.4103/0022-3859.57393 1:STN:280:DC%2BD1MjjsVOnuw%3D%3D 19884741
43. GG Zhanel M DeCorby KA Nichol, et al. 2008 Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006) Can J Infect Dis Med Microbiol 19 243 249 19412382
44. DL Stevens Y Ma DB Salmi, et al. 2007 Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus J Infect Dis 195 202 211 10.1086/510396 1:CAS:528:DC%2BD2sXhs1amtr0%3D 17191165
45. R Saliba L Paasch A El Solh 2009 Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines Immunopharmacol Immunotoxicol 31 583 588 10.3109/08923970902838672 1:CAS:528:DC%2BD1MXhtlekt7fO 19874226
46. P Baudoux S Lemaire O Denis, et al. 2010 Activity of quinupristin/ dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes J Antimicrob Chemother 65 1228 1236 10.1093/jac/dkq110 1:CAS:528:DC%2BC3cXmtFOhtr4%3D 20378672
47. PM Schlievert 2001 Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses J Allergy Clin Immunol 108 S107 S110 10.1067/mai.2001.117820 1:CAS:528: DC%2BD3MXotFWlsb0%3D 11586276
48. J Darenberg N Ihendyane J Sjolin 2003 Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial Clin Infect Dis 37 333 340 10.1086/376630 1:CAS:528:DC%2BD3sXnt1yktLo%3D 12884156
49. K Kato T Sakamoto K Ito 2007 Gamma-globulin inhibits superantigen-induced lymphocyte proliferation and cytokine production Allergol Int 56 439 444 10.2332/allergolint.O-06-462 1:CAS:528:DC%2BD1cXmsFGqsA%3D%3D 17965583
50. J Darenberg B Söderquist BH Normark A Norrby-Teglund 2004 Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome Clin Infect Dis 38 836 842 10.1086/381979 1:CAS:528:DC%2BD2cXjtlCksrk%3D 14999628